Stephens Inc. AR Sells 8,678 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL)

Stephens Inc. AR reduced its stake in shares of Castle Biosciences, Inc. (NASDAQ:CSTL) by 36.5% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 15,095 shares of the company’s stock after selling 8,678 shares during the period. Stephens Inc. AR owned 0.05% of Castle Biosciences worth $431,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the stock. The Manufacturers Life Insurance Company raised its position in Castle Biosciences by 7.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 10,122 shares of the company’s stock worth $220,000 after purchasing an additional 675 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Castle Biosciences by 10.7% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,882 shares of the company’s stock worth $215,000 after purchasing an additional 952 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in Castle Biosciences by 6.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 18,034 shares of the company’s stock worth $400,000 after purchasing an additional 1,131 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its position in Castle Biosciences by 64.6% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,335 shares of the company’s stock worth $152,000 after purchasing an additional 2,093 shares during the last quarter. Finally, Truist Financial Corp raised its position in Castle Biosciences by 20.5% during the 2nd quarter. Truist Financial Corp now owns 14,217 shares of the company’s stock worth $310,000 after purchasing an additional 2,420 shares during the last quarter. 92.60% of the stock is owned by institutional investors.

Analysts Set New Price Targets

CSTL has been the subject of a number of recent analyst reports. Lake Street Capital increased their price target on Castle Biosciences from $34.00 to $40.00 and gave the stock a “buy” rating in a report on Tuesday. KeyCorp increased their price target on Castle Biosciences from $28.00 to $36.00 and gave the stock an “overweight” rating in a report on Tuesday. Scotiabank increased their price target on Castle Biosciences from $37.00 to $44.00 and gave the stock a “sector outperform” rating in a report on Wednesday. Canaccord Genuity Group increased their price target on Castle Biosciences from $35.00 to $42.00 and gave the stock a “buy” rating in a report on Tuesday, October 29th. Finally, Robert W. Baird increased their price target on Castle Biosciences from $37.00 to $39.00 and gave the stock an “outperform” rating in a report on Tuesday. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $37.88.

Castle Biosciences Stock Performance

Shares of CSTL opened at $32.66 on Thursday. The company has a debt-to-equity ratio of 0.02, a current ratio of 8.12 and a quick ratio of 7.92. The stock has a 50-day moving average of $30.78 and a 200-day moving average of $25.72. The company has a market cap of $901.64 million, a PE ratio of 163.30 and a beta of 0.99. Castle Biosciences, Inc. has a one year low of $16.20 and a one year high of $35.84.

Castle Biosciences (NASDAQ:CSTL) last issued its earnings results on Monday, November 4th. The company reported $0.08 EPS for the quarter, beating the consensus estimate of ($0.06) by $0.14. The company had revenue of $85.78 million during the quarter, compared to the consensus estimate of $78.55 million. Castle Biosciences had a negative return on equity of 0.77% and a negative net margin of 1.08%. During the same period last year, the business posted ($0.26) EPS. On average, equities research analysts predict that Castle Biosciences, Inc. will post -0.58 EPS for the current fiscal year.

Insider Buying and Selling at Castle Biosciences

In other Castle Biosciences news, insider Derek J. Maetzold sold 1,972 shares of Castle Biosciences stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $32.27, for a total transaction of $63,636.44. Following the completion of the transaction, the insider now owns 91,664 shares in the company, valued at approximately $2,957,997.28. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Castle Biosciences news, insider Derek J. Maetzold sold 1,972 shares of Castle Biosciences stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $32.27, for a total transaction of $63,636.44. Following the completion of the transaction, the insider now owns 91,664 shares in the company, valued at approximately $2,957,997.28. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Derek J. Maetzold sold 986 shares of Castle Biosciences stock in a transaction dated Tuesday, October 8th. The shares were sold at an average price of $30.27, for a total value of $29,846.22. Following the transaction, the insider now owns 93,636 shares of the company’s stock, valued at $2,834,361.72. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 19,694 shares of company stock worth $563,497. Insiders own 7.20% of the company’s stock.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.